Notably, making use of available clinical data, we observed that all the aforementioned genes except SCN5A, increasing or decreasing the mRNA level in the same direction as Omomyc, could confer a significant survival advantage in patients with breast cancer (Supplementary Fig. S6D). Here, SCN5A is linked to breast carcinoma.